Issa F. Khouri, M.D.
Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine
Present Title & Affiliation
Dual/Joint/Adjunct Appointment
Professor Medicine & Internist, Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
Licenses & Certifications
| 2017 | American Board of Hematology |
| 1997 | American Board of Medical Oncology |
| 1990 | Texas Medical License |
| 1989 | American Board of Internal Medicine |
| 1988 | Ohio Medical License |
Experience & Service
Faculty Academic Appointments
Associate Professor/Associate Internist, Department of Blood and Marrow Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX, 1999 - 2004
Assistant Professor/Assistant Internist, Department of Blood and Marrow Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX, 1995 - 1999
Instructor/Assistant Internist, Department of Blood and Marrow Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX, 1993 - 1995
Administrative Appointments/Responsibilities
Bone Marrow Center Medical Director, The University of Texas MD Anderson Cancer Center, Houston, TX, 2005 - 2014
Supervisor, Outpatient Ambulatory Allogeneic Transplant Center, Department of Blood and Marrow Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX, 1997 - 2002
Extramural Institutional Committee Activities
Member, M. D. Anderson Medical Records Committee, The University of Texas MD Anderson Cancer Center, 2023 - Present
Reviewer, M. D. Anderson Credential Committee of Medical Staff, The University of Texas MD Anderson Cancer Center, 2020 - Present
Associate Member, M. D. Anderson Institutional Review Board Committees, The University of Texas MD Anderson Cancer Center, 2013 - Present
Member, M. D. Anderson Central Medical Education Committee, The University of Texas MD Anderson Cancer Center, 2009 - Present
Editorial Activities
Member of Editorial Review Board, Biology of Blood and Marrow Transplantation, 2007 - Present
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2019. Biological & Immunotherapy approaches with Checkpoint Inhibitors for SCT in Lymphoma. Conference. Biological & Immunotherapy approaches with Checkpoint Inhibitors for SCT in Lymphoma. Houston, TX, US.
- 2018. Role of Allogeneic Stem Cell Transplant. Conference. Role of Allogeneic Stem Cell Transplant. Houston, TX, US.
- 2004. Allogeneic adoptive immunotherapy for CLL. Conference. Allogeneic adoptive immunotherapy for CLL. Houston, TX, US.
Regional Presentations
- 2019. CLL. Conference. CLL. Dallas, TX, US.
National Presentations
- 2025. Post-transplant bendamustine (PT-BEN) with or without cyclophosphamide for gvhd prophylaxis after haplo-identical or matched unrelated donor transplants: A phase I/II trial. Poster. ASH Annual Meeting. Orlando, FL, US.
- 2024. Addition of Inotuzumab Ozogamicin to Melphalan Plus Fludarabine Reduced-Intensity Conditioning Regimen of Allogeneic Transplantation in Patients with Acute Lymphoblastic Leukemia and Aggressive Lymphoid Malignancies: A Phase II Prospective Trial. Poster. ASH Annual Meeting. San Diego, CA, US.
- 2023. Addition of inotuzumab ozogamicin to the conditioning regimen of allogeneic stem cell transplantation for relapsed CD22 (+) lymphoid malignancies: Long-term survival results. Conference. Addition of inotuzumab ozogamicin to the conditioning regimen of allogeneic stem cell transplantation for relapsed CD22 (+) lymphoid malignancies: Long-term survival results. San Diego, CA, US.
- 2023. In the era of BCL-2 & BTK inhibitors and CAR-T therapy, is there a role for Allogeneic SCT in CLL?. Conference. In the era of BCL-2 & BTK inhibitors and CAR-T therapy, is there a role for Allogeneic SCT in CLL?. Gilbert, AZ, US.
- 2023. Clinical Immersion in Acute Myeloid Leukemia (AML), Role of Hematopoietic Stem Cell Transplantation (HSCT) in AML. Conference. Clinical Immersion in Acute Myeloid Leukemia (AML), Role of Hematopoietic Stem Cell Transplantation (HSCT) in AML. Houston, TX, US.
- 2018. Evolving Strategies in Lymphoma. Conference. Evolving Strategies in Lymphoma. Bethesda, MD, US.
- 2018. Evolving Transplant Strategies for Lymphoma. Conference. Evolving Transplant Strategies for Lymphoma. Nashville, TN, US.
- 2018. The role of transplantation in CLL. Conference. The role of transplantation in CLL. Irving, TX, US.
- 2016. The Evolving Tale of Allogeneic Transplantation in Lymphoma. Conference. The Evolving Tale of Allogeneic Transplantation in Lymphoma. New York City, NY, US.
- 2016. Number of prior lines of therapy and mixed chimerism but not Ki-67 impact long-term outcomes of non-myeloablative allogeneic stem cell transplantation (alloSCT) in patients with relapsed mantle cell lymphoma (MCL). Conference. Number of prior lines of therapy and mixed chimerism but not Ki-67 impact long-term outcomes of non-myeloablative allogeneic stem cell transplantation (alloSCT) in patients with relapsed mantle cell lymphoma (MCL). Atlanta, GA, US.
- 2014. Evolving Therapy of MCL: Is There Still a Role for Upfront Transplant?. Conference. Evolving Therapy of MCL: Is There Still a Role for Upfront Transplant?. New York City, NY, US.
- 2014. Current and future of high dose therapy in Mantle Cell Lymphoma. Conference. Current and future of high dose therapy in Mantle Cell Lymphoma. New York City, NY, US.
- 2013. Bfr (bendamustine, fludarabine, rituximab) Nonmyeloablative Allogeneic Conditioning: A Novel Regimen Inducing Immunosuppression Without Myelosupression. Conference. Bfr (bendamustine, fludarabine, rituximab) Nonmyeloablative Allogeneic Conditioning: A Novel Regimen Inducing Immunosuppression Without Myelosupression. New Orleans, LA, US.
- 2012. Update of Transplant in CLL. Conference. Update of Transplant in CLL. Houston, TX, US.
- 2011. Nonmyeloablative Allogeneic Conditioning with Bendamustine in Combination with Fludarabine and Rituximab. Conference. Nonmyeoablative Allogeneic Conditioning with Bendamustine in Combination with Fludarabine and Rituximab. San Diego, CA, US.
- 2011. Nonmyeloablative Allogeneic Stem Cell Transplantation with/ or without yttrium Ibritumomab Tiuxetan Is Curative for Relapsed Follicular Lymphoma: Median 9 Year Follow-up Results. Conference. Nonmyeloablative Allogeneic Stem Cell Transplantation with/ or without yttrium Ibritumomab Tiuxetan Is Curative for Relapsed Follicular Lymphoma: Median 9 Year Follow-up Results. San Diego, CA, US.
- 2010. Transplant in CLL-When, How, and What to Expect. Conference. Transplant in CLL-When, How, and What to Expect. Houston, TX, US.
- 2009. Methods and Strategies for Monitoring relapse Following Allogeneic Stem Cell Transplantation. Lymphoma Monitoring. Conference. Methods and Strategies for Monitoring relapse Following Allogeneic Stem Cell Transplantation. Lymphoma Monitoring. Washington, DC, US.
- 2009. Role of Monoclonal Antibodies in Transplantation for CLL. Conference. Role of Monoclonal Antibodies in Transplantation for CLL. Tampa, FL, US.
- 2009. Stem Cell Transplantation with 90yttrium Ibritumomab Tiuxetan(90YIT) in Non-Hodgkin's Lymphoma (NHL): Observations From PET Pre-Treatment Imaging and Responses in Allografted Refractory Follicular Histologies. Conference. American Society of Hematology Annual Meeting. New Orleans, LA, US.
- 2008. Transplants for CLL. Conference. Transplants for CLL. New York, NY, US.
- 2008. Non-myeloablative vs Autologous Stem Cell Transplantation for MCL. Conference. Non-myeloablative vs Autologous Stem Cell Transplantation for MCL. Dallas, US.
- 2007. Directions for Research- “Transplants for Follicular Lymphoma. Conference. Directions for Research- “Transplants for Follicular Lymphoma. Arlington, VA, US.
- 2007. Nonmyeloablative Allogeneic Transplantation for Relapsed Follicular Lymphoma: Continuous Complete Remission with Longer-Follow-up. Conference. American Society of Hematology Annual Meeting. Atlanta, GA, US.
- 2007. 90Yttrium Ibritumomab Tiuxetan/BEAM/Ritiximab vs. BEAM/Rituximab and Autologous Stem Cell Transplantation (ASCT) for Relapsed Chemosensitive Diffuse Large B-Cell Lymphoma (DLBCL): Impact of the IPI and PET Status. Conference. 90Yttrium Ibritumomab Tiuxetan/BEAM/Ritiximab vs. BEAM/Rituximab and Autologous Stem Cell Transplantation (ASCT) for Relapsed Chemosensitive Diffuse Large B-Cell Lymphoma (DLBCL): Impact of the IPI and PET Status. Atlanta, GA, US.
- 2007. Non-myeloablative Stem Cell Transplantation Overcomes the Adverse Effects of Treatment Resistance and High B2M in Patients With Mantle Cell Lymphoma. Conference. American Society of Hematology Annual Meeting. Atlanta, GA, US.
- 2006. What is The Role of Transplantation in CLL. Conference. What is The Role of Transplantation in CLL. Sarasota, FL, US.
- 2006. Transplantation for Mantle Cell Lymphoma. Conference. Honolulu, HI, US.
- 2006. Reduced-Intensity Conditioning for Lymphoma. Conference. American Society of Hematology Annual Meeting Educational Session. Orlando, FL, US.
- 2005. Longer Follow-Up Confirms a Low Relapse Rate after Non-Myeloablative Allogeneic Transplantation (NMT) for Non- Hodgkin’s Lymphoma (NHL), Including Patients with PET or Gallium-Avid Disease. Conference. American Society of Hematology Annual Meeting. Atlanta, GA, US.
- 2005. Autologous Stem Cell (AUTO) vs. Non-Myeloablative Allogeneic Transplantation (NMT) after High-Dose Rituximab (HD-R) – Containing Conditioning Regimens for Relapsed Chemosensitive Follicular Lymphoma (FL). Conference. American Society of Hematology Annual Meeting. Atlanta, GA, US.
- 2004. Transplantation in CLL- how and who. Conference. Leukemia 2004, Towards a Cure. Houston, TX, US.
- 2004. Advances in stem cell transplantation for lymphoid malignancies: Direction from clinical trial. Conference. University of Southern California, Hematology Grand Rounds. Los Angeles, CA, US.
- 2003. Nonablative allogeneic transplantation for lymphoma. Conference. Nonablative allogeneic transplantation for lymphoma. Houston, TX, US.
- 2003. Evaluating monoclonal therapy for b-cell malignancies. Conference. The University of Mississippi. Jackson, MS, US.
- 2002. What role will transplantation play in CLL treatment?. Conference. What role will transplantation play in CLL treatment?. Philadelphia, PA, US.
- 2002. Maximizing oncology therapy: a focus on chronic lymphocytic leukemia. Conference. Darnail Army Community Hospital. Fort Hood, TX, US.
- 2002. Mantle cell lymphoma. Conference. Mantle cell lymphoma. Los Angeles, CA, US.
- 2002. Chronic lymphocytic leukemia: Should non-myeloablative transplants replace conventional transplants?. Conference. Leukemia 2002 towards the cure. Miami, FL, US.
- 2002. Minitransplants-The way to the future or a dead end street”. Conference. Saint Francis/Mt. Sinai Regional Cancer CenteThirteenth Annual Hematology-Oncology Symposium,. Hartford, CT, US.
- 2002. Comparative survival for nonablative and ablative allogeneic transplantation for CLL. Conference. IX International Workshop on CLL. San Diego, CA, US.
- 2002. CLL and low grade lymphoma-update of the M. D. Anderson Cancer Center experience. Conference. Chairman of Lymphoid Malignancies Session, Third International Workshop on Non-myeloablative Stem Cell Transplantation. Captiva Island, FL, US.
- 2001. Transplant Options for Non-Hodgkin’s Lymphoma. Conference. Annual Cancer Symposium Lakeland Hospital. St Joseph, MI, US.
- 2001. Non-myeloablive Stem Cell Transplantation for Lymphomas. Conference. Corporate Symposium of the Lymphoma…The Next Questions Meeting. Washington, DC, US.
- 2001. Prolonged failure free survival and molecular responses with nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma. Conference. American Society of Hematology Annual meeting. Orlando, FL, US.
- 2000. Reducing Toxicity and Induction of Graft-versus-Malignancy. Conference. Reducing Toxicity and Induction of Graft-versus-Malignancy. Taipei, US.
- 2000. Bone Marrow Transplantation for Lymphoma and CLL,” Houston, Texas. Conference. Bone Marrow Transplantation for Lymphoma and CLL,” Houston, Texas. Houston, TX, US.
- 2000. The potential role of anti-CD20 monoclonal antibodies in transplantation. Conference. The potential role of anti-CD20 monoclonal antibodies in transplantation. Houston, TX, US.
- 2000. Bone marrow transplant for lymphoma. Conference. Bone marrow transplant for lymphoma. Houston, TX, US.
- 2000. Transplantation in CLL. Conference. Transplantation in CLL. Houston, TX, US.
- 2000. Fludarabine-based non-myeloablative transplantation for hematologic malignancies. Conference. Fludarabine-based non-myeloablative transplantation for hematologic malignancies. Dallas, TX, US.
- 2000. Mini-allogeneic stem cell transplantation for relapsed/refractory lymphoma with aggressive histologies. Conference. American Society of Clinical Oncology Annual Meeting. New Orleans, LA, US.
- 1999. Update on Hyper-CVAD for mantle cell lymphoma. Conference. Update on Hyper-CVAD for mantle cell lymphoma. Palm Springs, CA, US.
- 1999. Update of the HCVAD regimen followed by stem cell transplantation (SCT) in mantle cell lymphoma (MCL). Conference. American Society of Hematology Annual Meeting. New Orleans, LA, US.
- 1999. Cell Processing – Mobilization and Preservation. Conference. American Society of Hematology Annual Meeting, Chairman of Simultaneous Session. New Orleans, LA, US.
- 1998. Allogeneic Transplantation Using a Non-Ablative Regimen: Induction of GVL as a Therapeutic Modality. Conference. Allogeneic Transplantation Using a Non-Ablative Regimen: Induction of GVL as a Therapeutic Modality. San Diego, CA, US.
- 1998. Cell Processing. Conference. American Society of Hematology Annual Meeting, Chairman of a Simultaneous Session. Miami, FL, US.
- 1998. Allogeneic and autologous transplantation for chronic lymphocytic leukemia. Conference. International Bone Marrow Transplant Registry and Autologous Blood and Marrow Transplant Registry Annual Meeting. Keystone, FL, US.
- 1997. Mantle cell lymphoma: Improved outcome with hyper CVAD/high dose methotrexate-cytarabine followed by autologous or allogeneic stem cell transplantation. Conference. American Society of Hematology Annual Meeting. San Diego, CA, US.
- 1997. Preliminary report of an active regimen for mantle cell lymphoma. Conference. American Society of Hematology Annual Meeting. San Diego, CA, US.
- 1996. Leukemia-The Next Questions "The Role of Autologous and Allogeneic Transplantation for CLL". Conference. Leukemia-The Next Questions "The Role of Autologous and Allogeneic Transplantation for CLL". New Orleans, LA, US.
- 1996. Autologous Transplantation for Breast Cancer and Solid Tumors. Conference. Autologous Transplantation for Breast Cancer and Solid Tumors. Wichita, KS, US.
- 1995. Engraftment and induction of GVL with fludarabine-based non-ablative preparative regimen in patients with chronic lymphocytic leukemia and lymphoma. Conference. American Society of Hematology Annual Meeting. Orlando, FL, US.
- 1994. High-dose chemotherapy and unpurged autologous stem cell transplantation for chronic myelogenous leukemia: The M. D. Anderson Experience. Conference. American Society of Hematology Annual Meeting. Nashville, TN, US.
- 1992. B-cell depletion using immunomagnetic beads for autologous bone marrow transplantation in chronic lymphocytic leukemia. Conference. 21st Annual Meeting of the International Society for Experimental Hematology. New York, NY, US.
International Presentations
- 2024. Invited Speaker: AlloHCT should be the referred therapy for Richter’s transformation. Invited. Houston, US.
- 2024. Chair Session: Cellular Therapy. Invited. Houston, US.
- 2022. Allotransplant in low grade lymphoma. Conference. Allotransplant in low grade lymphoma, BM.
- 2022. Maintenance approaches post HSCT in AML. Conference. Maintenance approaches post HSCT in AML, BM.
- 2019. Aggressive Lymphoma Workshop, Role of Transplantation. Conference. Aggressive Lymphoma Workshop, Role of Transplantation. Bologna, IT.
- 2017. Modern strategies in stem cell transplantation. Conference. Modern strategies in stem cell transplantation. St. Petersburg, RU.
- 2015. CLL & MCL. Conference. CLL & MCL. Berlin, DE.
- 2015. BFR (bendamustine, fludarabine, rituximab) Allogeneic Conditioning Improves Survival in CLL. Conference. BFR (bendamustine, fludarabine, rituximab) Allogeneic Conditioning Improves Survival in CLL. Lugano, CH.
- 2014. Allogeneic Transplantation in Follicular Lymphoma. Conference. Allogeneic Transplantation in Follicular Lymphoma. Bologna, IT.
- 2014. Transplantation for Lymphoma: Who, When and How. Conference. Transplantation for Lymphoma: Who, When and How. Hangzhou, CN.
- 2012. Role of Stem Cell Transplantation in the Management of Leukemia. Conference. Role of Stem Cell Transplantation in the Management of Leukemia. Doha, QA.
- 2012. ASCT in lymphoma, when and how?-RIC Allogeneic SCT in CLL and Low-grade-lymphoma. Conference. ASCT in lymphoma, when and how?-RIC Allogeneic SCT in CLL and Low-grade-lymphoma, SA.
- 2012. Hematopoietic stem cell transplantation-When and what to offer: Autologous vs allogeneic HCT? -Role of allogeneic stem cell transplantation in AML-Role of allogeneic stem cell transplantation in ALL. Conference. Hematopoietic stem cell transplantation-When and what to offer: Autologous vs allogeneic HCT? -Role of allogeneic stem cell transplantation in AML-Role of allogeneic stem cell transplantation in ALL. Beirut, LB.
- 2011. Hematopoietic stem cell transplantation for non-Hodgkin lymphoma and chronic lymphocytic leukemia: Changing paradigms. Conference. Hematopoietic stem cell transplantation for non-Hodgkin lymphoma and chronic lymphocytic leukemia: Changing paradigms. Guilin, US.
- 2011. Presenting at the MDA-organized "LEUKEMIA AND LYMPHOMA - East and West are together" conference. Conference. Presenting at the MDA-organized "LEUKEMIA AND LYMPHOMA - East and West are together" conference. Dubrovnik, HR.
- 2011. Bendamustine in Combination with Fludarabine and Rituximab: A Phase I-II Novel Nonmyeloablative Conditioning for Allogeneic Stem Cell Transplantation (AST) in Patients with Lymphoid Malignancies. Conference. Bendamustine in Combination with Fludarabine and Rituximab: A Phase I-II Novel Nonmyeloablative Conditioning for Allogeneic Stem Cell Transplantation (AST) in Patients with Lymphoid Malignancies. Lugano, CH.
- 2011. Autologous Stem Cell Transplantation (ASCT) as Upfront or Salvage Therapy for Non-cutaneous T Cell Lymphoma (TCL): The M.D. Anderson Cancer Center (MDACC) Experience. Conference. Autologous Stem Cell Transplantation (ASCT) as Upfront or Salvage Therapy for Non-cutaneous T Cell Lymphoma (TCL): The M.D. Anderson Cancer Center (MDACC) Experience. Lugano, CH.
- 2010. Allogenic Transplant in Diffuse-large-B-Cell Lymphoma-American Perspectives. Conference. Allogenic Transplant in Diffuse-large-B-Cell Lymphoma-American Perspectives. Bologna, IT.
- 2009. Supportive Care and rare Leukemias. Conference. Supportive Care and rare Leukemias. Brussels, BE.
- 2009. Stem Cell Transplantation for Follicular Lymphoma- How Can we Improve Results?. Conference. Stem Cell Transplantation for Follicular Lymphoma- How Can we Improve Results?. Brussels, BE.
- 2009. Stem Cell Transplantation for Lymphoma and Myeloma. Conference. Stem Cell Transplantation for Lymphoma and Myeloma. Beirut, LB.
- 2008. Allogeneic Stem Cell Transplantation in Combination with anti-CD20 for Relapsed Lymphoma. Conference. Allogeneic Stem Cell Transplantation in Combination with anti-CD20 for Relapsed Lymphoma. Berlin, DE.
- 2008. Non-myeloablative vs Autologous Stem Cell Transplantation for MCL. Conference. Non-myeloablative vs Autologous Stem Cell Transplantation for MCL. Lugano, CH.
- 2008. Management of Lymphoma with Transplantation. Conference. Management of Lymphoma with Transplantation. Amman, JO.
- 2008. Evolving Paradigm in CLL Therapy. Conference. Evolving Paradigm in CLL Therapy. Amman, JO.
- 2008. Management of Lymphoma with Stem Cell Transplantation. Conference. Management of Lymphoma with Stem Cell Transplantation. Beijing, CN.
- 2006. Rituximab-based Conditioning for B-Cell Tumors: Autologous versus Allogeneic Transplantation. Conference. Rituximab-based Conditioning for B-Cell Tumors: Autologous versus Allogeneic Transplantation. Milan, IT.
- 2004. Allogeneic Transplantation in CLL, The MD Anderson experience. Conference. V. International Workshop of the German CLL Study Group. Kloster Irsee (Bavaria), DE.
- 2004. Advances in Stem Cell Transplantation for Lymphoma: Role of Monoclonal Antibodies. Conference. Kansai Medical University, The 21st Century Center of Excellence (CEO) Program- New Strategies for Treatment of Intractable Diseases. Awaji Island, JP.
- 2003. Nonablative transplants are a major advance in the management of indolent neoplasms. Conference. 8th Congress of the European Hematology Association, Schering AG sponsored satellite symposium. Lyon, FR.
- 2003. Allogeneic stem cell transplantation for CML: its role in the gleevec era. Conference. The Lebanese Society of Blood Transfusions. Beirut, LB.
- 2003. NST for NHL-the M. D. Anderson Cancer Center experience. Conference. 4th International Workshop on Non-myeloablative Stem Cell transplantation. Chairman of NST in lymphoma’s session, BM.
- 2002. Reduced intensity regimens: the M. D. Anderson’s experience. Conference. International Meeting on Chronic Lymphocytic Leukemia: is it a curable disease?. Bologna, IT.
- 2002. Controversies in the management of follicular lymphoma. Conference. 8th International Conference on Malignant Lymphoma, Schering AG Satellite. Lugano, CH.
- 2002. Biovision satellite. “Transplantation in indolent lymphoid disorders. Conference. 8th International Conference on Malignant Lymphoma. Lugano, CH.
- 2002. What’s new in the management of mantle cell lymphoma. Conference. 7th International Congress on Hematologic Malignancies. Whistler, CA.
- 2001. Non-myeloablative preparative regimens: How relevant for myeloid and lymphoid malignancies,”. Conference. Non-myeloablative preparative regimens: How relevant for myeloid and lymphoid malignancies,”. Seoul, KR.
- 2001. Non-myeloablative transplants in Non Hodgkin Lymphoma. Conference. IV Simposio Internacional. Montevideo, UY.
- 2001. The use of monoclonal antibodies in the treatment of NHL. Conference. IV Simposio Internacional. Montevideo, UY.
- 2001. NST for Lymphoid Malignancies. Conference. NST for Lymphoid Malignancies. St. Martin.
- 2000. Rituximab – Therapeutic Monoclonal Antibody for Patients with Non-Hodgkin’s Lymphoma in Hematology. Conference. Rituximab – Therapeutic Monoclonal Antibody for Patients with Non-Hodgkin’s Lymphoma in Hematology. Kurashiki, JP.
- 2000. Chairman Session: Bone Marrow Transplantation Non-myeloablative high-dose therapy for bone marrow transplant. Conference. Chairman Session: Bone Marrow Transplantation Non-myeloablative high-dose therapy for bone marrow transplant. Beirut, LB.
- 2000. Chairman Session: Bone Marrow Transplantation Non-myeloablative high-dose therapy for bone marrow transplant. Conference. Chairman Session: Bone Marrow Transplantation Non-myeloablative high-dose therapy for bone marrow transplant. Beirut, LB.
- 2000. Non-myeloablative allogeneic stem cell transplantation, the M. D. Anderson experience. Conference. Non-myeloablative allogeneic stem cell transplantation, the M. D. Anderson experience. Copenhagen, DK.
- 2000. Autologous and allogeneic transplantation for hematologic malignancies. Conference. Autologous and allogeneic transplantation for hematologic malignancies. Beirut, LB.
- 2000. Bone marrow transplantation in chronic lymphocytic leukemia, the M. D. Anderson experience Non-myeloablative allogeneic stem cell transplantation, the M. D. Anderson experience. Conference. Bone marrow transplantation in chronic lymphocytic leukemia, the M. D. Anderson experience Non-myeloablative allogeneic stem cell transplantation, the M. D. Anderson experience. Copenhagen, DK.
- 2000. Autologous bone marrow transplant in solid tumors. Conference. Autologous bone marrow transplant in solid tumors. Beirut, LB.
- 2000. Non-myeloablative stem cell transplantation. Conference. Non-myeloablative stem cell transplantation. Fukuoka, JP.
- 2000. Fludarabine-based regimens for lymphoid malignancies. Conference. Fludarabine-based regimens for lymphoid malignancies. San Lucia.
- 1999. Mini-allogeneic transplantation. Conference. Mini-allogeneic transplantation. Durban, ZA.
- 1999. Treatment for low grade lymphomas. Conference. Treatment for low grade lymphomas. Montevideo, UY.
- 1999. Mini-stem cell transplant and donor lymphocyte infusions. Conference. Mini-stem cell transplant and donor lymphocyte infusions. Beirut, LB.
- 1999. Mini-allotransplant for AML. Conference. Mini-allotransplant for AML. Munster, DE.
- 1999. Future development of pentostatin: Immunomodulation and allogeneic transplantation. Conference. Future development of pentostatin: Immunomodulation and allogeneic transplantation. San Juan, PR.
- 1999. Allogeneic transplantation for mantle cell lymphoma: molecular remissions and evidence of graft-versus-malignancy. Conference. VII International Conference on Malignant Lymphoma. Lugano, CH.
- 1999. Mini-Allogeneic transplantation and induction of graft-versus-malignancy. Conference. Peripheral Blood Stem Cell Transplantation: 10th Symposium, Special lecture. Mulhouse, FR.
- 1998. Hematopoietic Progenitor Transplantation in CLL. Conference. Hematopoietic Progenitor Transplantation in CLL. Bavaria, DE.
- 1998. Allogeneic Mini-Transplants: Concepts and Clinical Results. Conference. Allogeneic Mini-Transplants: Concepts and Clinical Results. Koln, DE.
- 1998. Fludarabine in Bone Marrow Transplantation. Conference. Fludarabine in Bone Marrow Transplantation. Mont Tremblant, CA.
- 1997. Stem Cell Transplantation For Chronic Lymphocytic Leukemia. Conference. Stem Cell Transplantation For Chronic Lymphocytic Leukemia. Crete, GR.
- 1997. New Approaches to Allogeneic, Autologous and Mini Stem Cell Transplantation. Conference. New Approaches to Allogeneic, Autologous and Mini Stem Cell Transplantation. Beirut, LB.
- 1997. Update on Stem Cell Transplantation. Conference. Update on Stem Cell Transplantation. Amman, JO.
- 1997. Preliminary report of a new active regimen for aggressive mantle cell lymphoma. Conference. 23rd Annual Meeting of the European Group for Blood and Marrow Transplantation, Aix-Les-Bains, FR.
- 1997. Induction of graft-versus-leukemia using fludarabine-based allogeneic mini-transplants as treatment for lymphoid malignancies. Conference. 26th Annual Meeting of the International Society for Experimental Hematology. Cannes, FR.
- 1995. Chronic lymphocytic leukemia and peripheral blood stem cell transplantation. Conference. Chronic lymphocytic leukemia and peripheral blood stem cell transplantation. Montevideo, UY.
Formal Peers
- 2022. Why Stem Cell Transplantation in 2022. Invited. Madison, WI, US.
- 2017. Advances in Allogeneic Transplantation in Lymphoma. Invited. Salt Lake City, UT, US.
- 2017. Evolving Strategies in Lymphoma. Invited. Stanford, CA, US.
- 2017. Evolving Strategies in Lymphoma. Invited. Lexington, KY, US.
- 2016. Evolving Transplant Strategies for Lymphoma and CLL. Invited. Charleston, SC, US.
- 2015. Evolving Transplant Strategies for Lymphoma and CLL. Invited. Tucson, AZ, US.
- 2015. New Transplant Strategies for Lymphoma and CLL. Invited. St. Louis, MO, US.
- 2015. New Transplant Strategies for Lymphoma and CLL. Invited. Phoenix, AZ, US.
- 2015. Is there still any indication for allogeneic SCT in CLL?. Invited. Berlin, DE.
- 2015. Is autologous SCT still the appropriate upfront treatment for MCL?. Invited. Berlin, DE.
- 2015. New Transplant Strategies for Lymphoma. Invited. New York, NY, US.
- 2015. Evolving Transplant Strategies for Lymphoma and CLL. Invited. New Haven, CT, US.
- 2012. Transplantation for Lymphoma: Changing Paradigms. Invited. Cincinnati, OH, US.
- 2010. Role of Stem Cell Transplantation for Follicular Lymphoma. Invited. Montreal, CA.
- 2010. Role of Stem Cell Transplantation for Follicular Lymphoma. Invited. Montreal, CA.
- 2008. Updates in Lymphoma. Invited. Chicago, IL, US.
- 2008. Autologous and Allogeneic Transplantation for Lymphoma. Invited. New York, NY, US.
- 2006. Role of Bone Marrow Transplantation in the Treatment of Lymphoma. Invited. Little Rock, AR, US.
- 2003. The role of monoclonal antibodies in stem cell transplantation. Invited. Miami, FL, US.
- 2003. Transplant options for b-cell malignancies. Invited. Chicago, IL, US.
- 2003. Mini-transplants for CLL. Invited. Patterson, NJ, US.
- 2002. Nonmyeloablative transplantation for indolent lymphoid malignancies. Invited. Dallas, TN, US.
- 2002. Transplant options for lymphomas. Invited. Los Angeles, CA, US.
- 2002. Transplantation in indolent lymphomas. Invited. Los Angeles, CA, US.
- 2002. Non-myeloablative transplantation for lymphoma. Invited. New Orleans, LA, US.
- 2001. Mini-transplants and Graft-versus-Tumor. Invited. Sendai, JP.
- 2001. Allogeneic transplantation and immunomodulation for Chronic Myelogenous Leukemia. Invited. Morioka, JP.
- 2000. Transplantation for Non-Hodgkin’s Lymphoma,”. Invited. Tokyo, JP.
- 2000. BMT in NHL. Invited. San Antonio, TX, US.
- 2000. BMT in CLL: an update. Invited. San Antonio, TX, US.
- 2000. Blood Marrow Transplant in Lymphoma,”. Invited. Atlanta, GA, US.
- 1999. Allogeneic mini transplantation for lymphoid malignancies. Invited. Berlin, DE.
- 1999. Mini-allogeneic transplantation for lymphoid malignancies. Invited. Oklahoma City, OK, US.
- 1998. Mini-allo transplantation for lymphoid malignancies. Invited. Seattle, WA, US.
- 1998. Hematopoietic Transplantation for CLL. Invited. Omaha, NE, US.
Grant & Contract Support
| Date: | 2022 - 2023 |
| Title: | 2018-0972: Post-Transplant Bendamustine (PT-BEN) for GVHD Prophylaxis |
| Funding Source: | MDACC/IRG |
| Role: | PI |
| ID: | 60659 |
| Date: | 2019 - 2026 |
| Title: | A Pilot Study of Lenalidomide Alternating with Ipilimumab Post Allogeneic and Autologous Stem Cell Transplantation (2012-0947) |
| Funding Source: | BMS |
| Role: | PI |
| ID: | 56403 |
| Date: | 2018 - 2026 |
| Title: | Addition of Inotuzumab Ozogamicin Pre- and Post-Allogeneic Transplantation (2018-0860) |
| Funding Source: | Pfizer |
| Role: | PI |
| ID: | CS2019-00056667 |
| Date: | 2015 - 2018 |
| Title: | Targeting BTK with Ibrutinib after Autologous and Allogeneic Stem Cell Transplantation in “Double-Hit” B-Cell Lymphoma |
| Funding Source: | Pharmacyclics |
| Role: | PI |
| Date: | 2014 - 2016 |
| Title: | Lenalidomide Alternating with Ipilimumab After Allogeneic and Autologous Stem Cell Transplantation |
| Funding Source: | UTMDACC MDS/AML Moonshot Cell Therapy Project |
| Role: | Co-PI |
| Date: | 2013 - 2015 |
| Title: | Carfilzomib Consolidation Therapy after ASCT for MCL, TCL, and DLBCL |
| Funding Source: | Onyx Pharmaceuticals, Inc |
| Role: | PI |
| Date: | 2012 - 2015 |
| Title: | Zevalin-Containing Nonmyeloablative Conditioning for SCT |
| Funding Source: | Spectrum Pharmaceuticals, Inc |
| Role: | PI |
| ID: | G0000152 |
| Date: | 2012 - 2015 |
| Title: | Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) Added to Fludarabine, Bendamustine and Rituximab and Allogeneic Transplantation for CD22 positive-Lymphoid Malignancies |
| Funding Source: | Pfizer, Inc |
| Role: | PI |
| ID: | CS2012-00036746RG |
| Date: | 2011 - 2016 |
| Title: | Novel Approaches to High-risk Deletion 17p Myeloma |
| Funding Source: | Onyx Pharmaceuticals, Inc |
| Role: | PI |
| ID: | 36364 |
| Date: | 2011 - 2017 |
| Title: | Chemotherapy plus Ofatumumab followed by G-CSF for Mobilization of Peripheral Blood Stem Cells in Patients with Non-Hodgkins Lymphomas |
| Funding Source: | Glaxo Smith Kline |
| Role: | PI |
| ID: | CS2010-00031144MA |
| Date: | 2010 - 2012 |
| Title: | A Double-Blind, Randomized Phase III Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo |
| Funding Source: | Bayer |
| Role: | PI |
| ID: | CS2010-00032234MA 01 |
| Date: | 2009 - 2014 |
| Title: | Nonmyeloablative stem cell transplantation with or without Revlimid maintenance for CLL |
| Funding Source: | Celgene |
| Role: | PI |
| ID: | CS2009-00026296JW |
| Date: | 2008 - 2016 |
| Title: | Fludarabine, Bendamustine and Rituximab (FBR) Non-myeloablative Allogenic Conditioning for Patients with Lymphoid Malignancies |
| Funding Source: | Cephalon, Inc |
| Role: | PI |
| ID: | SR2009-00026285EB |
| Date: | 2006 - 2014 |
| Title: | Bortezomib and Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients with Lymphoid Malignancies |
| Funding Source: | Millennium Pharmaceutical Inc |
| Role: | PI |
| ID: | CS2006-0017713JW |
| Date: | 2006 - 2019 |
| Title: | Immunotherapy with NK cell, Rituximab and rhu-GMCSF, in Non-myeloablative Allogeneic Stem Cell Transplantation |
| Funding Source: | Berlex Laboratories, Inc |
| Role: | PI |
| ID: | CS22006-00018164J |
| Date: | 2003 - 2010 |
| Title: | Nonmyeloablative allogeneic transplantation with rituximab-containing conditioning regimen for mantle cell lymphoma |
| Funding Source: | Lymphoma Research Foundation |
| Role: | PI |
| ID: | CF2003-0000986HM |
| Date: | 2003 - 2008 |
| Title: | Autologous and allogeneic transplantation for T-cell lymphoma: Impact of Campath-1H and soluble CD52 |
| Funding Source: | Berlex Laboratories, Inc |
| Role: | PI |
| ID: | CS2003-00009465SP |
| Date: | 2003 - 2005 |
| Title: | 90Y Zevalin, BEAM and rituximab in autologous stem cell transplantation for lymphoma |
| Funding Source: | IDEC Pharmaceuticals |
| Role: | PI |
| ID: | CS2003-00009760SP |
| Date: | 2002 - 2014 |
| Title: | Safety and efficacy of 90Y Zevalin in nonmyeloablative transplantation for lymphoid malignancies |
| Funding Source: | IDEC Pharmaceuticals Corporation |
| Role: | PI |
| ID: | CS2002-00006998HM 01 |
| Date: | 2002 - 2007 |
| Title: | Safety and efficacy of Campath-1H in nonmyeloablative allogeneic stem cell transplantation |
| Funding Source: | IDEC Pharmaceuticals |
| Role: | PI |
| ID: | CS-02-6998 |
| Date: | 1999 - 2002 |
| Title: | Mini-allogeneic transplantation |
| Funding Source: | G & P Charitable Foundation |
| Role: | PI |
| ID: | CS 00-050 |
| Date: | 1999 - 2001 |
| Title: | Rituximab and autologous transplantation for indolent lymphoid malignancies |
| Funding Source: | Immunex |
| Role: | PI |
| ID: | LS 00-009 |
| Date: | 1999 |
| Title: | Rituximab in mini-allotransplants |
| Funding Source: | Genentech |
| Role: | PI |
| Date: | 1997 - 1997 |
| Title: | Mini-transplants for chronic lymphocytic leukemia and Lymphoma |
| Funding Source: | Berlex Laboratories, Inc |
| Role: | PI |
| ID: | CS 97-003 |
Selected Publications
Professional Educational Materials
- Khouri I, Champlin RE. Chronic Lymphocytic Leukemia. In: On Call in Bone Marrow Transplantation. RG Landes Co., Austin and Chapman & Hall, 1996.
Book Chapters
- Giralt S, Khouri I, Champlin R. Non-myeloablative conditioning: Induction of graft-versus-disease effect as a therapeutic modality. In: Clinical Bone Marrow and Blood Stem Cell Transplantation. Third. Cambridge University Press, 357-368, 2004.
- Khouri I, Champlin R. Allogeneic transplantation for lymphoma and chronic lymphocytic leukemia. In: Thomas’ hematopoietic cell transplantation. Third. Blackwell Publishing, 1105-1115, 2004.
- Khouri I, Giralt S, Champlin R. Non-myeloablative hematopoietic transplantation and induction of graft-versus-malignancy. In: Non-myeloablative allogeneic transplantation. Kluwer Academic Publishers, 137-147, 2002.
- Korbling M, Khouri I. Allogeneic stem cell transplantation using non-myeloablative transplant regimens. In: High-Dose Therapy and Transplantation of Haematopoietic Stem Cells. Blackwell Wissenschafts-Verlag, 175-184, 2000.
- Khouri I, Giralt S, Champlin R. Fludarabine-based nonmyeloablative transplantation for hematologic malignancies. In: Autologous Blood and Marrow Transplantation. Proceedings of the Tenth International Symposium. Autologous Blood and Marrow Transplantation. Proceedings of the Tenth International Symposium, 346-353, 2000.
- Giralt S, Khouri I, Champlin R. Non-myeloablative conditioning: Induction of graft-versus-leukemia effect as a therapeutic modality. In: Clinical Bone Marrow and Blood Stem Cell Transplantation. Second. Cambridge University Press, 1182-1188, 2000.
- Hosing C, Khouri I. Non-myeloablative stem cell transplantation for lymphoid malignancies using fludarabine-based regimens. In: Non-myeloablative stem cell transplantation (NST). Darwin Scientific Publishing, Ltd, 105-110, 2000.
- Champlin RE, Khouri I, van Besien K. Allogeneic Blood and Marrow Transplantation for Chronic Lymphocytic Leukemia and Lymphoma. In: Hematopoietic Cell Transplantation,. Second. Blackwell Science, Inc, 882-902, 1999.
- Khouri I, Sanchez FG, Deisserorth AB. Molecular biology of the leukemias. In: Cancer, Principles and Practice of Oncology. Fifth. J.B. Lippicott, 2285-2292, 1997.
- Deisseroth, AB, Kantarjian H, Andreef M, Talpaz M, Keating M J, Khouri I, Champlin RE. Chronic Leukemia. In: Cancer, Principles and Practice of Oncology. Fifth Edition. J. B. Lippincott, 2321-2338, 1997.
- Giralt S, Estey E, Albitar M, van Besien K, Rondon G, Anderlini P, O’Brien S, Khouri I, Gajewski J, Mehra R, Claxton D, Andersson B, Beran M, Przepiorka D, Koller C, Komblau S, Korbling M, Keating M, Kantarjian H, Champlin RE. Engraftment of Allogeneic Hematopoietic Progenitor Cells with Purine Analog Containing Chemotherapy, Harnessing Graft-Versus-Leukemia Without Myeloablative Therapy. In: Proceedings of the Eight International Symposium. Proceedings of the Eight International Symposium, 103, 1997.
- Khouri I, Kantarjian H, Talpaz M, Andreeff M, Lee MS, Champlin RE, Deisseroth AB. Chronic myelogenous leukemia. In: Clinical Oncology. Churchill Livingstone, 2035-2051, 1995.
- Khouri I, Reading CL, Vriesendorp HM, Andersson BS, Przepiorka D, van Besien K, Deisseroth AB, Champlin RE. High dose cyclophosphamide, total body irradiation and autologous bone marrow transplantation (BMT) for chronic lymphocytic leukemia. In: Autologous Bone Marrow Transplantation: Proceedings of the seventh international symposium. Autologous Bone Marrow Transplantation: Proceedings of the seventh international symposium, 235-238, 1995.
- Khouri I, Deisseroth AB. Genetic modification of hematopoietic stem cells for therapy of solid tumors and hematopoietic Neoplasms. In: Hematopoietic Stem Cells: Biology and Therapeutic Applications. Marcel Dekker, Inc, 219-227, 1995.
- Khouri I, Kantarjian H, Talpaz M, Claxton D, Cornball S, Deisseroth AB. Molecular diagnosis and therapy for hematopoietic neoplasms. In: The Molecular Basis of Cancer. WB Saunders Co, 280-293, 1995.
- Khouri I, Deisseroth AB. Advances in the biology and treatment of chronic myelogenous leukemia. In: Hematopoietic Growth Factors, Oncogenes and Cytokines in Clinical Hematology. Karger, 160-177, 1994.
- Przepiorka D, Huh YO, Khouri I, et al. Graft failure and graft-vs-host disease after subtotal T-cell-depleted marrow transplantation: Correlations with marrow hematopoletic and lymphoid subsets. In: Advances in bone marrow purging and processing: Fourth International Symposium. Advances in bone marrow purging and processing: Fourth International Symposium, 557-563, 1994.
- Deisseroth, AB, Andreeff M, Champlin RE, Keating M, Kantarjian H, Khouri I, Talpaz M. Chronic Leukemias. In: Cancer: Principles and Practice of Oncology. Fourth. J.B. Lippincott, 1965-1983, 1993.
- Khouri I, Glisson B. Small Cell Lung Cancer. In: Medical Oncology, A Comprehensive Review, 117-126, 1993.
- Yuan T, Zhou YQ, Herst CV, Reading C, Ellerson D, Etkin M, Khouri I, Kantarjian H, Talpaz M, Deisseroth AB. Molecular approaches to purging of chronic myelogenous leukemia marrow in autologous transplantation. In: Advances in Bone Marrow Purging and Processing Progress in Clinical and Biological Research, Volume 377. Wiley-Liss, Inc, 227-230, 1992.
Patient Reviews
CV information above last modified August 26, 2026